Australia's CSL is wielding the axe, cutting its workforce by 15% – around 3,000 positions – while announcing plans to spin its vaccines unit into a standalone company. The decision to demerge the CSL ...

Billions have been wiped from CSL's valuation following profit downgrades and pressure from competition. Analysts say the healthcare giant now faces a "show me" moment, with doubts growing about its ...

Two weeks before he announced CSL’s latest shock earnings downgrade, Gordon Naylor was scheduled to sit down with investors in Melbourne to brief them on the healthcare giant’s financial performance.

// Licensed under the Apache License, Version 2.0 (the "License"); // you may not use this file except in compliance with the License. // You may obtain a copy of the ...

From blue-chip royalty to bin fire, the company’s staggering fall is a brutal reckoning for the Australian icon lost in its own complacency and hubris. Logic tells us worrying about round numbers in ...

In a 90-day review, CSL told the market it would take another $US5bn ($A6.9bn) non-cash impairment. The first $1.5bn of this was recognised during the first-half ...

CSL has slashed its revenue projection for the fiscal year from $15.8 billion to $15.2 billion, in another indication of the Australian company’s financial distress since its ill-fated 2022 ...

CSL trades at a discount despite owning a dominant, hard-to-replicate global plasma-derived therapies infrastructure. Transformation Program targets $500–$550M in annual pre-tax cost reductions by ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CSL (ASX:CSL) has outlined a restructuring plan that ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. CSL has started construction ...

Eli Lilly & CSL seal a deal for clazakizumab partitions rights to maximize lifecycle value. CSL retains ESKD focus as Lilly prioritizes commercialization. CSL and Eli Lilly have struck a strategic ...